Methods and compositions related to immunogenic fibrils
AssigneesBoard of Regents, The University of Texas System, The University of Chicago
InventorsJoel H. Collier, Jai S Rudra
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention are directed to fibrillar adjuvants. Epitopes assembled into nanofibers by a short synthetic fibrillization domain elicited high antibody titers in the absence of any adjuvant.
Claims19
An immunogenic composition comprising a peptide fibril coupled to at least one antigen that is presented multiple times on the peptide fibril, wherein the peptide fibril comprises two or more of a self-assembling peptide, the self-assembling peptide comprising an amino acid sequence of FKFEFKFE (SEQ ID NO:
- 25);
- QQKFQFQFEQQ (SEQ ID NO:
- 1);
- KFQFQFE (SEQ ID NO:
- 2);
- QQRFQFQFEQQ (SEQ ID NO:
- 3);
- QQRFQWQFEQQ (SEQ ID NO:
- 4);
- FEFEFKFKFEFEFKFK (SEQ ID NO:
- 5);
- QQRFEWEFEQQ (SEQ ID NO:
- 6);
- QQXFXWXFQQQ (where X denotes ornithine) (SEQ ID NO:
- 7);
- FKFEFKFEFKFE (SEQ ID NO:
- 8);
- FKFQFKFQFKFQ (SEQ ID NO:
- 9);
- AEAKAEAKAEAKAEAK (SEQ ID NO:
- 10);
- AEAEAKAKAEAEAKAK (SEQ ID NO:
- 11);
- AEAEAEAEAKAKAKAK (SEQ ID NO:
- 12);
- RADARADARADARADA (SEQ ID NO:
- 13);
- RARADADARARADADA (SEQ ID NO:
- 14);
- SGRGYBLGGQGAGAAAAAGGAGQGGYGGLGSQG (SEQ ID NO:
- 15);
- EWEXEXEXEX (where X=V, A ,S, or P) (SEQ ID NO:
- 16);
- WKXKXKXKXK (where X=V, A, S, or P) (SEQ ID NO:
- 17);
- KWKVKVKVKVKVKVK (where X=V, A, S, or P) (SEQ ID NO:
- 18);
- LLLLKKKKKKKKLLLL (SEQ ID NO:
- 19);
- VKVKVKVKVDPPTKVKVKVKV (SEQ ID NO:
- 20);
- VKVKVKVKVDPPTKVKTKVKV (SEQ ID NO:
- 21);
- KVKVKVKVKDPPSVKVKVKVK (SEQ ID NO:
- 22);
- VKVKVKVKVDPPSKVKVKVKV (SEQ ID NO:
- 23);or VKVKVKTKVDPPTKVKTKVKV (SEQ ID NO:
- 24), wherein the self-assembling peptide comprises one or more D amino acids.
A self-assembling antigen composition comprising an antigen coupled to a fibril-forming peptide, the fibril-forming peptide selected from a peptide having an amino acid sequence of FKFEFKFE (SEQ ID NO:
- 25);
- QQKFQFQFEQQ (SEQ ID NO:
- 1);
- KFQFQFE (SEQ ID NO:
- 2);
- QQRFQFQFEQQ (SEQ ID NO:
- 3);
- QQRFQWQFEQQ (SEQ ID NO:
- 4);
- FEFEFKFKFEFEFKFK (SEQ ID NO:
- 5);
- QQRFEWEFEQQ (SEQ ID NO:
- 6);
- QQXFXWXFQQQ (where X denotes ornithine) (SEQ ID NO:
- 7);
- FKFEFKFEFKFE (SEQ ID NO:
- 8);
- FKFQFKFQFKFQ (SEQ ID NO:
- 9);
- AEAKAEAKAEAKAEAK (SEQ ID NO:
- 10);
- AEAEAKAKAEAEAKAK (SEQ ID NO:
- 11);
- AEAEAEAEAKAKAKAK (SEQ ID NO:
- 12);
- RADARADARADARADA (SEQ ID NO:
- 13);
- RARADADARARADADA (SEQ ID NO:
- 14);
- SGRGYBLGGQGAGAAAAAGGAGQGGYGGLGSQG (SEQ ID NO:
- 15);
- EWEXEXEXEX (where X =V, A ,S, or P) (SEQ ID NO:
- 16);
- WKXKXKXKXK (where X =V, A, S, or P) (SEQ ID NO:
- 17);
- KWKVKVKVKVKVKVK (where X =V, A, S, or P) (SEQ ID NO:
- 18);
- LLLLKKKKKKKKLLLL (SEQ ID NO:
- 19);
- VKVKVKVKVDPPTKVKVKVKV (SEQ ID NO:
- 20);
- VKVKVKVKVDPPTKVKTKVKV (SEQ ID NO:
- 21);
- KVKVKVKVKDPPSVKVKVKVK (SEQ ID NO:
- 22);
- VKVKVKVKVDPPSKVKVKVKV (SEQ ID NO:
- 23);
- or VKVKVKTKVDPPTKVKTKVKV (SEQ ID NO:
- 24), wherein the fibril-forming peptide has one or more D amino acids.
Dependencies are inferred from the claim text.